3Kwok PY, Chen X. Detection of single nucleotide polymorphisms [J]. Curr Issues Mol Biol,2003(5) :43 -60.
4Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non - small cell lung cancer to gefitinib [ J ]. N Engl J Med,2004,350 (21): 2129 - 2139.
5Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy[ J]. Science, 2004,304(5676) :1497 - 1500.
6Eberhard DA,Johnson BE,AmLer LC, et al. Mutations in the epidermal growth factor receptor and in K - RAS are predictive and prognostic indicators in patients with non - small cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J]. J Clin Oncol,2005,23(25): 5900 -5909.
7Kosaka T, Yatabe Y, Endo H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications [ J ]. Cancer Res ,2004,64:8919 - 8923.
8Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological feature associated with epidermal growth factor receptor gene mutations in lung cancers[J]. J Natl Cancer Inst,2005,97(5) :339 - 346.
9Fukuoka M, Yano S, Giaccone G, et al. Final results from a phase Ⅱ trial of ZD1839 (Iressa) for patients with advanced non - small cell lung cancer (IDEAL- 1 ) [ J]. Proc ASCO,2002,21: 298a.
10Kris M,Natale RB,Hert RS,et al. A phase Ⅱ trial of ZD1839 ( Iressa) in dvanced non - small cell lung cancer (NSCLC) patients who had failed platinum - and docetaxel - based regimen ( IDEAL -2 ) [J]. Proc ASC0,2002,21 : 292a.
